Navigation Links
Pharmacyclics Announces Interim Results From Two Ongoing Phase 2,Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat,Recurrent Non-Small Cell Lung Cancer

WAILEA, Hawaii and SUNNYVALE, Calif., June 27, 2007 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. today announced preliminary results from two open-label, multi-center Phase 2 clinical trials supporting the potential use of Xcytrin(R) (motexafin gadolinium) Injection, the company's lead product candidate, in combination with Alimta(R) (pemetrexed) and in combination with Taxotere(R) (docetaxel) as a second-line treatment for patients with non-small cell lung cancer (NSCLC) who failed at least one platinum-based chemotherapy regimen. The results were presented today at the Eighth International Lung Cancer Congress in Wailea, Hawaii.

The first ongoing study is evaluating Xcytrin plus Alimta and has enrolled 27 patients of which 20 are evaluable for response at this time. Patients are receiving 15mg/kg Xcytrin with a standard dose of Alimta and treatment is repeated every 21 days. Seventeen patients (85%) receiving Xcytrin and Alimta have achieved stabilization of their tumors, with 10 of the 17 still on treatment for up to nine cycles. The median survival time and median time to progression have not been reached, with estimated actuarial survival of 69% at 12 months. Patients still on treatment remain under evaluation for tumor response. The most common severe (Grade 3 or higher) side effects were asthenia (10.3%), pneumonia (10.3%), thrombocytopenia (10.3%), and neutropenia (6.9%).

The other ongoing study is evaluating Xcytrin plus Taxotere and has enrolled 24 patients of which 14 are evaluable for response at this time. Patients are given 15mg/kg Xcytrin with a standard dose of Taxotere and treatment is repeated every 21 days. Thirteen patients (87%) receiving Xcytrin and Taxotere have achieved stabilization of their tumors, with four still on treatment. The median survival time is 8.2 months and the median time to progression is 8.7 months. Patients still on treatment remain under evaluation for
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Pharmacyclics Announces Promising Results From Phase 2 Clinical Trial of Xcytrin in Recurrent, Metastatic Non-Small Cell Lung Cancer
2. Pharmacyclics Announces Presentations and Published Abstracts on Xcytrin at The 2007 American Society of Clinical Oncology Annual Meeting
3. Pharmacyclics Identifies Functional Biomarkers for its Novel HDAC Inhibitor and Demonstrates Preclinical Anti-Tumor Activity with Brutons Tyrosine Kinase Inhibitors
4. Pharmacyclics Announces Presentations on Its Novel and Selective HDAC and Brutons Tyrosine Kinase Inhibitor Compounds
5. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
(Date:5/15/2008)...rland, May 15 /- Ergonex Pharma today...ministration (FDA) has,granted orphan drug designa...rterial hypertension (PAH). Terguride is currently...al in Europe., "The FDA,s grant of orphan drug de...ngthens our development program by offering regula...
(Date:5/15/2008)...la., May 15 /- Tigris Pharmaceuticals...ive Research and,Development Agreement (CRADA) wit...te on clinical and preclinical development of AFP-...ent. AFP-464 is converted to,metabolites which bin...nd,apoptosis., This is part of a four-year CRADA ...
(Date:5/15/2008)...ity Remains for an Antiplatelet Therapy that, Comb...Combination of Plavix/Iscover and Aspirin, Acc...ALTHAM, Mass., May 15 /- Decision Res...visory firms for pharmaceutical and,healthcare iss... offers,improvement in patient compared to Sanofi-...
(Date:5/15/2008)...ted soon after CEA Trial data reports in third qua...NCISCO, May 15 /- VIA Pharm... company focused on the development of,compounds f...ced today that,it has completed patient enrollment...CS study is one of three Phase 2 trials investigat...
Breaking Medicine Technology:Terguride Receives FDA Orphan Drug Designation for the Treatment of Pulmonary Arterial Hypertension 2Tigris Pharmaceuticals Signs CRADA with the National Cancer Institute 2Tigris Pharmaceuticals Signs CRADA with the National Cancer Institute 3Daiichi Sankyo/Eli Lilly's Effient and Astrazeneca's Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction 2Daiichi Sankyo/Eli Lilly's Effient and Astrazeneca's Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction 3VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial 2VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial 3VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial 4VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial 513 specialty health care organizations endorse joint principles of PCMH 16989 113 specialty health care organizations endorse joint principles of PCMH 16989 213 specialty health care organizations endorse joint principles of PCMH 16989 3Barbra Streisand endows program at Cedars Sinai womens heart center 16987 1Barbra Streisand endows program at Cedars Sinai womens heart center 16987 2Genetic Engineering 26amp 3B Biotechnology News reports on growing use of cell based assays 2917 1Saliva can help diagnose heart attack study shows 2915 1Saliva can help diagnose heart attack study shows 2915 2
...- Data presented,today at a major medical meeting ...administered once-daily for five days is as,effect...mg) for 10,days for the treatment of complicated u...ritis (AP). , Ortho-McNeil, Inc., the company that...during a scientific session at the annual,meeting ...
...ew study,demonstrated that the active ingredient i... may improve symptom relief rates in adults,with i... These,results were presented as a late-breaker at...nternational meeting of digestive disease,speciali...tone were nearly,twice as likely to achieve an ove...
Other Medicine Technology:Five Days of LEVAQUIN(R) as Effective as 10 Days of Ciprofloxacin,in Complicated Urinary Tract Infections and Acute Pyelonephritis 2Five Days of LEVAQUIN(R) as Effective as 10 Days of Ciprofloxacin,in Complicated Urinary Tract Infections and Acute Pyelonephritis 3Five Days of LEVAQUIN(R) as Effective as 10 Days of Ciprofloxacin,in Complicated Urinary Tract Infections and Acute Pyelonephritis 4New Study Demonstrates that Lubiprostone May Improve Symptom Relief,Rates in Adults with Irritable Bowel Syndrome with Constipation,(IBS-C) 2New Study Demonstrates that Lubiprostone May Improve Symptom Relief,Rates in Adults with Irritable Bowel Syndrome with Constipation,(IBS-C) 3New Study Demonstrates that Lubiprostone May Improve Symptom Relief,Rates in Adults with Irritable Bowel Syndrome with Constipation,(IBS-C) 4New Study Demonstrates that Lubiprostone May Improve Symptom Relief,Rates in Adults with Irritable Bowel Syndrome with Constipation,(IBS-C) 5New Study Demonstrates that Lubiprostone May Improve Symptom Relief,Rates in Adults with Irritable Bowel Syndrome with Constipation,(IBS-C) 6
(Date:5/15/2008)..., In the wake of divorce, illness, violence and o...oung children are liable to experience temporary s... their knapsack for kindergarten. Published in th...community-wide study from Rochester, New York, war...ng difficulties and that these separations are goo...
(Date:5/15/2008)... INDIANAPOLIS, May 15 /PRNewswire-FirstCall/ -... into treatment decisions may fare better as a,res...ll lung cancer (NSCLC),clinical trial. Data from t...LIMTA(R) (pemetrexed for injection), will be prese...ciety of Clinical Oncology (ASCO) in Chicago,Ill....
(Date:5/15/2008)..., Washington, DC -- With the goal of tailoring ca... Georgetown University Medical Center today presen...p doctors more reliably assess treatment efficacy ... can take several weeks and sometimes months to de...g because it can take that long to observe any sig...
(Date:5/15/2008)..., , HOUSTON - Celecoxib, the anti-inflammato...x, has proven to be safe and reduces a specific pr... the lung, according to a study from The Universit...ing demonstrates the significance of COX-2 inhibit...t higher risk of developing the disease. , The s...
Breaking Medicine News(10 mins):Health News:Separation from mom, dad linked with learning trouble in kids 2Health News:Separation from mom, dad linked with learning trouble in kids 3Health News:ASCO Study Confirms Importance of Histology in Treatment of Non-Small Cell Lung Cancer With ALIMTA (pemetrexed for injection) 2Health News:ASCO Study Confirms Importance of Histology in Treatment of Non-Small Cell Lung Cancer With ALIMTA (pemetrexed for injection) 3Health News:ASCO Study Confirms Importance of Histology in Treatment of Non-Small Cell Lung Cancer With ALIMTA (pemetrexed for injection) 4Health News:ASCO Study Confirms Importance of Histology in Treatment of Non-Small Cell Lung Cancer With ALIMTA (pemetrexed for injection) 5Health News:ASCO Study Confirms Importance of Histology in Treatment of Non-Small Cell Lung Cancer With ALIMTA (pemetrexed for injection) 6Health News:ASCO Study Confirms Importance of Histology in Treatment of Non-Small Cell Lung Cancer With ALIMTA (pemetrexed for injection) 7Health News:Study suggests blood test can help improve treatment outcomes for breast cancer patients 2Health News:Celebrex shows benefit in first-of-its-kind lung cancer chemoprevention trial 2Health News:Celebrex shows benefit in first-of-its-kind lung cancer chemoprevention trial 3
...y Indian home now finds itself in the limelight wi...ses to fight// many tubborn inflammations and dege...seers as recorded in the ancient scripts of Ayurve...ed at the University of Arizona College of Medicin...
...iotherapy department to dogs and cats ailing from ...rvatives//. To effectively manage the ?24m debt a... from the staff that a pets’ clinic could be insti...ilized equipments to good use and also deal with t...
...that could put an end to reconstructive surgery fo...ected that the stem cells derived the patient’s ow... In the preliminary 3-year program of animal rese...on to scaffold structures that will serve as a pla...
...people with Type 2 Diabetes, named ‘Diabetes Care’... Insurance//. Speaking at the inauguration of the...ce and Dr.Mohan’s Diabetes Specialties Centre, Shi..., ICICI Prudential Life Insurance, said, "With ove...
Other Medicine News:Health News:Pet Peeves: Conservatives Howl at Proposal to Share NHS Hosp by Pets and People 2
...ational reference laboratory and a worldwide leade...t. ARUP offers an extensive test menu of highly co...tomic pathology. Owned by the University of Utah, ...of the nation's university teaching hospitals and ...
...ational reference laboratory and a worldwide leade...t. ARUP offers an extensive test menu of highly co...tomic pathology. Owned by the University of Utah, ...of the nation's university teaching hospitals and ...
...ational reference laboratory and a worldwide leade...t. ARUP offers an extensive test menu of highly co...tomic pathology. Owned by the University of Utah, ...of the nation's university teaching hospitals and ...
...ational reference laboratory and a worldwide leade...t. ARUP offers an extensive test menu of highly co...tomic pathology. Owned by the University of Utah, ...of the nation's university teaching hospitals and ...
Medicine Products: